today announced an expansion of its VEVYE ® Access for All ("VAFA") program to include patients currently prescribed Klarity-C Drops ®, a compounded cyclosporine 0.1% product manufactured and ...

Harrow (HROW) announced an expansion of its Vevye Access for All program to include patients currently prescribed Klarity-C Drops, a compounded cyclosporine 0.1% product manufactured and ...

IHEEZO Unit Volume Growth: 43% increase in Q4 compared to the previous quarter. VEVYE Prescription Growth: 44% increase in Q4 over the prior quarter. Harrow Inc (NASDAQ:HROW) reported a record ...

Baum, CEO. “This strong finish, driven by over 40% quarter-over-quarter growth in both IHEEZO unit demand and VEVYE prescriptions, showcases market uptake for our expanding portfolio and the ...

Existing Klarity-C Patients to Have Access to VEVYE for $59 Per Bottle As a result of today’s announcement, beginning immediately, more than 25,000 patients across the U.S. will be able to ...